PharmaFocus Today – Page 26 – media

Focused on Autoimmune Disease and Oncology Drug Development, with Cumulative Losses Exceeding 300 Million Yuan Over Three Years

Recently, Ganzhou Hemei Pharmaceutical Co., Ltd. (hereinafter referred to as “Hemei Pharmaceutical”), headquartered in Ganzhou, Jiangxi, formally submitted its prospectus to the Hong Kong Stock Exchange, planning to list on the Main Board of Hong Kong. SDIC Securities Financing (Hong Kong) Limited acted as the sole sponsor. According to the prospectus reviewed by Daily Economic News, Hemei Pharmaceutical was founded in 2002 and focuses on developing small-molecule drugs for autoimmune diseases and oncology. The company currently has one approved product and multiple pipeline drugs in clinical stages. However, Hemei Pharmaceutical has yet to achieve profitability. The prospectus indicates that from 2023 to the first half of 2025, the company accumulated a net loss of over RMB 350 million, with R&D expenditure being the primary cost. To date, the company has completed seven rounds of financing, with a valuation of RMB 3.9 billion after the most recent round. Pipeline Covers 7 ...
- Source: drugdu
- 96
- December 3, 2025
In the multi-billion dollar cardiovascular market, these two targets have become the “new favorites”

In recent years, the field of cardiovascular disease treatment has been undergoing a profound transformation. PCSK9 and Lp(a), two emerging targets, have emerged as hotly contested areas for multinational pharmaceutical companies, ushering in a new golden age for cardiovascular disease treatment. 1 Two golden targets are coming Atherosclerotic cardiovascular disease (ASCVD) is a collective term for a group of diseases affecting blood vessels and the heart throughout the body caused by atherosclerosis, including coronary heart disease, cerebrovascular disease, and peripheral artery disease. ASCVD is one of the leading causes of death worldwide. The Global Burden of Disease Study shows that ischemic heart disease has consistently ranked as the leading cause of death globally in both 1990 and 2021. In China, there are approximately 500 million adults with dyslipidemia, of whom about 120 million have hypercholesterolemia. Statins are the cornerstone of lipid-lowering therapy for dyslipidemia. They reduce cholesterol synthesis by inhibiting ...
- Source: drugdu
- 159
- December 3, 2025
Another milestone for Baili Tianheng

Recently, Baileyn announced that it has received a milestone payment of $250 million from BMS. Previously, in December 2023, Baili Tianheng entered into an exclusive licensing and collaboration agreement with BMS for its world-first-in-class EGFR×HER3 bispecific antibody ADC project iza-bren (BL-B01D1) to jointly develop and commercialize it globally. Under the agreement, BMS will pay the company an upfront payment of $800 million and two contingent payments of $250 million in the near future; upon achieving development, registration, and sales milestones, the company will receive additional payments of up to $7.1 billion; the potential total transaction value could reach up to $8.4 billion. In September of this year, Baili Tianheng’s global Phase II/III pivotal registration clinical trial, IZABRIGHT-Breast01, reached a milestone, triggering this payment. This is the largest milestone payment for a single ADC asset in any disclosed overseas transaction of a domestic innovative drug to date. Baili Tianheng is collaborating ...
- Source: drugdu
- 118
- December 3, 2025
WuXi Biologics and the Qatar Free Zones Authority signed a strategic cooperation memorandum.

WuXi Biologics announced on December 2nd that it has signed a strategic cooperation memorandum with the Qatar Free Zone Authority (QFZ) to expand its global service network and professional business capabilitiesThis strategic partnership lays the foundation for WuXi Biologics to establish its first integrated CRDMO center in the Middle East within the Qatar Free Zone. https://finance.eastmoney.com/a/202512023580217070.html
- Source: drugdu
- 107
- December 2, 2025
Eli Lilly lowers out-of-pocket price of Zepbound weight loss drug

　 LillyThe company announced that, starting December 1, the self-paid price of Zepbound through the LillyDirect platform will be reduced from the previous $349-$499 per month to $299-$449. 　　The starting dose has been reduced to $299 per month, the 5mg dose to $399 per month, and all higher doses to a uniform $449 per month. Zepbound’s list price is approximately $1086 per month. This price reduction primarily targets the single-dose vial of Zepbound, which requires patients to self-inject, aiming to circumvent high prices and unstable insurance coverage.The barriers to coverage should be addressed to provide more affordable treatment options for out-of-pocket patients. 　　This price reduction comes after the Trump administration pushed for an agreement to lower the price of GLP-1 drugs, following competition from Novo Nordisk.They have also recently lowered the price of their weight-loss drugs.Out-of-pocket prices for Wegovy and the diabetes medication Ozempic. https://finance.eastmoney.com/a/202512023579780327.html
- Source: drugdu
- 91
- December 2, 2025
China’s top-tier ADC “targets” lung cancer

In August of this year, Kelun Biotech’s market capitalization surpassed HK$100 billion for the first time, becoming a rising star in the innovative drug field. Since its listing on the Hong Kong Stock Exchange in July 2023, its share price and market capitalization have experienced dramatic ups and downs; however, setbacks have not hindered Kelun Biotech’s progress. Recently, Kelun Biotech announced that its domestically produced flagship ADC drug, saconduit (sac-TMT), in combination with Keytruda (pembrolizumab) in the first-line treatment of PD-L1 positive NSCLC, met its primary endpoint in the Phase III OptiTROP-Lung05 study. This marks another key step in Kelun Biotech’s globalization process, and domestically produced ADCs have officially launched their offensive in the lung cancer battlefield. 01 Phase 3 Success Sacubituzumab (sac-TMT) is an ADC targeting TROP2. The drug is composed of a humanized monoclonal antibody, sacituzumab, an enzymatically cleavable linker, and a novel topoisomerase I inhibitor, toxin T030. ...
- Source: drugdu
- 97
- December 2, 2025
AD therapy suffered two major setbacks in three days

The development of Alzheimer’s disease treatments has suffered a series of setbacks in the past few days: Novo Nordisk attempted to explore the disease-modifying effects of semaglutide in early Alzheimer’s disease by leveraging its potential role in metabolic and inflammatory regulation, but both large phase 3 trials failed to show a delay in cognitive or functional decline; at almost the same time, Johnson & Johnson’s anti-tau antibody also failed to demonstrate any effect on disease progression in an interim study. 01 A Real-World Test of the GLP-1 Extension Path Novo Nordisk’s EVOKE and EVOKE+ results, announced on November 24, marked a temporary halt to the exploration of GLP-1 drugs in the field of Alzheimer’s disease. These two trials enrolled 3,808 early-stage patients aged 55 to 85, aiming to evaluate whether the oral version of semaglutide could slow the rate of cognitive and functional decline over a two-year follow-up period. Novo ...
- Source: drugdu
- 100
- December 2, 2025
Global First Drug Candidate Approved for Both China and the United States with Double New Drug Application and Double Approval – Targeting Autoimmune Diseases

Zhongzheng Intelligent Finance & Research Leads Biolabs(09887) announced on December 1st evening that the company’s independently developed candidate drug LBL-047’s new drug clinical trial (IND) application was approved by the National Medical Products Administration (NMPA) on November 25th. According to the announcement, LBL-047 is the world’s first dual-specific fusion protein to achieve dual submissions and dual approvals in China and the United States. It is composed of a humanized anti-blood dendritic cell antigen 2 (BDCA2) antibody and a modified transmembrane activator and calcineurin binding molecule (TACI) extracellular domain. Currently, there are no drugs globally that simultaneously target plasma cell-like dendritic cells (pDC) and B cells and have been approved for clinical trials. This drug, with its unique mechanism of action, has the potential to be the first and the best among its kind. LBL-047 selectively eliminates pDC to reduce the production of type 1 interferons and inhibits the B cell ...
- Source: drugdu
- 80
- December 2, 2025
GLP-1 type weight-loss drugs mark a “new chapter” in the global fight against obesity

On Monday local time, the World Health Organization (WHO) stated that drugs such as Mounjaro have great potential in addressing the global obesity crisis, and it is estimated that 2 billion people worldwide will be affected by obesity by 2030. Given the significant efficacy of these drugs in assisting weight loss, this means that the health systems of various countries are entering a “new chapter” in treating obesity and its associated fatal diseases. This is also the first time that the WHO has recommended the use of GLP-1 drugs for the management of adult obesity, marking an important shift in the UN agency’s approach to obesity treatment. The WHO calls on countries to take measures to ensure that those in need of GLP-1 drugs can access these medications. It also points out that, typically, eligible adults should be able to use such drugs, but pregnant women should not use them. ...
- Source: drugdu
- 86
- December 2, 2025
Abbott Deploys a ‘Comprehensive Network’ with Innovative Technology

December 1, 2025, marks the 38th World AIDS Day. This year’s campaign theme, “Societal Co-governance, Integrity and Innovation, End AIDS,” aims to deepen the understanding of the importance and long-term nature of AIDS prevention and control work. Building on the review and continuation of past effective prevention and treatment experiences and exemplary practices, the theme further calls on all sectors of society to jointly shoulder the responsibility of AIDS prevention and control, strengthen exploration and innovation in HIV/AIDS intervention measures, and promote the high-quality development of AIDS prevention and control efforts. Viral testing is a critical component of AIDS prevention and control. As a leading global healthcare company, Abbott has been committed to continuously advancing and innovating in cutting-edge HIV testing technologies for the past four decades since launching the world’s first HIV antibody test kit in 1985, using accurate diagnosis to combat the threat of the disease. In 1985, ...
- Source: drugdu
- 92
- December 2, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.